



09/896811

COJR

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 7,060,828

Issue Date : June 13, 2006

Inventors : Thomas D. Madden et al.

Docket No. : 480208.407

Date : February 8, 2007

Certificate
FEB 14 2007
of Correction

Mail Stop Certificate of Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION

Commissioner for Patents:

A certificate of correction is respectfully requested in the above-identified patent.

The following errors have been made:

In the Title page, Item (56) References Cited, Other Publications, as acknowledged by the examiner in the office action dated July 13, 2005, --Apostolidou, E., G. Garcia-Manero, et al. "Phase I Study of OSI-211, a Novel Liposomal Topoisomerase 1 (Topo 1) Inhibitor, in Patients with Refractory Leukemia," *Blood*, 2002. Abstract #4575.-- was incorrectly recorded as "Apostolidou, E., G. Garcia-Manero, et al. "Phase I Study of OSI-211, a Novel Liposomal Topoisomerase 1 (Topo 1) Inhibitor, in Patients withs Refractory Leukemia," *Blood*, 2002. Abstract #4575." in the issued patent.


On page 4, Item (56) References Cited, Other Publications, as acknowledged by the examiner in the office action dated July 13, 2005, --Desjardins, J. P., D. L. Emerson, et al. "Biodistribution of NX 211, liposomal GI147211, in tumor bearing mice." *Proc Amer Assoc Cancer Res* 41:702, Mar. 2000. Abstract #4467.-- was incorrectly recorded as "Desjardins, J. P., D. L. Emerson, et al. "Biodistribution of NX 211, liposomal GI147211, in tumor bearing mice." *Proc Amer Assoc Cancer Res* 41702, Mar. 2000. Abstract #4467." in the issued patent.

Attached is the certificate of correction, which indicates the corrections to be made, by reference to the item number in the printed patent. Because the errors were made by

FEB 16 2007

Attached is the certificate of correction, which indicates the corrections to be made, by reference to the item number in the printed patent. Because the errors were made by the Patent Office, no fee is necessary. However if they are determined to be our errors, the Director is hereby authorized to charge payment of any fees associated with this communication to Deposit Account No. 19-1090.

Respectfully submitted,
SEED Intellectual Property Law Group PLLC


Carol D. Laherty
Registration No. 51,909

CDL:sw

Enclosures:

Certificate of Correction Form
Postcard

SEED Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 5400
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031
903701_1.DOC

FEB 16 2007

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 7,060,828
DATED : June 13, 2006
INVENTORS : Thomas D. Madden et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page

Item (56) Other Publications, "Apostolidou, E., G. Garcia-Manero, et al. "Phase I Study of OSI-211, a Novel Liposomal Topoisomerase 1 (Topo 1) Inhibitor, in Patients with Refractory Leukemia," *Blood*, 2002. Abstract #4575." should read as: --Apostolidou, E., G. Garcia-Manero, et al. "Phase I Study of OSI-211, a Novel Liposomal Topoisomerase 1 (Topo 1) Inhibitor, in Patients with Refractory Leukemia," *Blood*, 2002. Abstract #4575.--

Page 4

Item (56) Other Publications, "Desjardins, J. P., D. L. Emerson, et al. "Biodistribution of NX 211, liposomal GI147211, in tumor bearing mice." *Proc Amer Assoc Cancer Res* 41:702, Mar. 2000. Abstract #4467." Should read as --Desjardins, J. P., D. L. Emerson, et al. "Biodistribution of NX 211, liposomal GI147211, in tumor bearing mice." *Proc Amer Assoc Cancer Res* 41:702, Mar. 2000. Abstract #4467.--

MAILING ADDRESS OF SENDER:

PATENT NO. 7,060,828

Seed Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 5400
Seattle, Washington 98104

No. of additional copies

0

Burden hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 16 2007